Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CDK2/9 Inhibitor
ZLMT-12 is a potent CDK2/9 inhibitor, demonstrating IC50 values of 0.002 μM and 0.011 μM against CDK9 and CDK2, respectively. This compound is derived from tacrine and exhibits weak inhibition of acetylcholinesterase (IC50 = 19.023 μM) and butyrylcholinesterase (IC50 = 2.768 μM). ZLMT-12 is characterized by low toxicity and notable antiproliferative activity, effectively inducing apoptosis and facilitating cell cycle arrest in the S and G2/M phases. This compound serves as a valuable tool for research in cell cycle regulation and therapeutic development in cancer biology. -
ChA Inhibitor
α-NETA is a potent noncompetitive inhibitor of choline acetyltransferase (ChA), exhibiting an IC50 value of 9 μM. Additionally, it displays strong antagonistic activity against aldehyde dehydrogenase 1A1 (ALDH1A1) with an IC50 of 0.04 µM and also targets chemokine-like receptor-1 (CMKLR1). While it shows some inhibitory effects on cholinesterase (ChE) and acetylcholinesterase (AChE) with higher IC50 values, α-NETA is notable for its anti-cancer properties, making it a valuable tool for research in cancer biology and neuropharmacology. -
AChE inhibitor
Picfeltarraenin IA is a triterpenoid compound isolated from *Picria fel-terrae* (*P. fel-terrae*) that functions as an acetylcholinesterase (AChE) inhibitor. It exhibits therapeutic potential for the treatment of herpes infections, cancer, and inflammatory conditions, making it a promising candidate for further pharmacological research. -
MAPK inhibitor
MAPK-IN-1 (Compound 2) is an inhibitor of the MAPK signaling pathway with demonstrated neuroprotective and anti-neuroinflammatory properties. It also exhibits acetylcholinesterase (AChE) inhibitory activity, with an IC₅₀ of 23.84 μM, contributing to enhanced cholinergic signaling. These combined actions make MAPK-IN-1 a promising candidate for research in Alzheimer's disease and other neurodegenerative disorders, where modulation of MAPK signaling and cholinergic function are of therapeutic interest. -
AChE Inhibitor
SCR1693 is a selective, reversible, orally active noncompetitive inhibitor of acetylcholinesterase (AChE), with an IC50 value of 0.68 μM, and exhibits calcium channel blocking properties. This compound effectively reduces tau phosphorylation levels and inhibits the generation and release of amyloid-beta (Aβ). Additionally, SCR1693 has been shown to restore insulin signaling and improve cognitive deficits, making it a valuable tool for studying Alzheimer's disease, particularly in cases complicated by type 2 diabetes mellitus. -
AChE Inhibitor
MR2938 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 5.04 μM. In addition to its enzymatic activity, MR2938 significantly reduces nitric oxide production, with an IC50 of 3.29 μM. This compound effectively mitigates neuroinflammation by inhibiting the MAPK/JNK and NF-κB signaling pathways. MR2938 is applicable for research focused on Alzheimer's disease and related neurodegenerative conditions. -
AChE Inhibitor/Metal Ion Chelating Agent
AD-35 is a potent acetylcholinesterase (AChE) inhibitor and a metal ion chelating agent, designed for research in Alzheimer’s disease. It demonstrates AChE and butyrylcholinesterase (BuChE) inhibition with IC50 values of 793 nM and 31,428 nM, respectively. AD-35 effectively chelates copper (Cu²⁺) and iron (Fe³⁺) ions, while exhibiting limited interaction with zinc (Zn²⁺). Additionally, AD-35 can inhibit amyloid-beta (Aβ) aggregation, destabilize pre-formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. Its ability to reduce neuroinflammation in rat models of Alzheimer's and improve cognitive performance underscores its potential in therapeutic research. -
ERK/BACE1/PSEN1 Inhibitor
L-Citronellol ((S)-3,7-Dimethyloct-6-en-1-ol) is an ERK/BACE1/PSEN1 inhibitor known for its anti-allergic and neuroprotective properties. This compound effectively inhibits mast cell activation and subsequent release of inflammatory mediators by targeting the ERK pathway. Additionally, L-Citronellol decreases the activity of BACE1, PSEN1, and acetylcholinesterase (AChE), while reducing TNF-α expression and lipid peroxidation, indicating its potential utility in multi-target approaches for Alzheimer's disease research. -
AChE Inhibitor
Linarin is a selective inhibitor of acetylcholinesterase (AChE), demonstrating oral bioavailability. This compound exhibits a range of biological activities, including anti-inflammatory, antioxidant, sedative, and antibacterial properties. Linarin is valuable for research in neurological disorders, osteoporosis, and cancer, providing insights into potential therapeutic applications across these areas. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-2 is a potent dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), demonstrating IC50 values of 1.8 nM and 71.0 nM, respectively. This compound exhibits significant neuroprotective properties and scavenges reactive oxygen species (ROS), alongside effectively chelating metal ions such as Fe2+ and Cu2+. Furthermore, BChE/HDAC6-IN-2 inhibits tau phosphorylation and presents moderate immunomodulatory effects, making it a valuable reagent for research into neurodegenerative diseases and related pathways. -
AChE/HDAC Inhibitor
AChE/HDAC-IN-1 is a potent dual inhibitor of acetylcholinesterase (AChE) and histone deacetylases (HDAC) with IC50 values of 0.12 nM and 0.23 nM, respectively. This compound also demonstrates antioxidant activity and metal chelating properties, making it a valuable tool in understanding neurodegenerative processes. AChE/HDAC-IN-1 is suitable for research applications related to Alzheimer's disease and other conditions associated with cholinergic dysfunction and epigenetic modifications. -
HDAC6 Inhibitor
HDAC6-IN-5 is a potent inhibitor of histone deacetylase 6 (HDAC6), demonstrating an IC50 of 0.025 μM. This compound effectively inhibits the self-aggregation of amyloid-beta 1-42 and acetylcholinesterase (AChE), with IC50 values of 3.0 μM and 0.72 μM, respectively. HDAC6-IN-5 has been shown to promote neurite outgrowth while exhibiting minimal neurotoxicity, making it a valuable tool for research in neurodegenerative disease and neuronal regeneration studies. -
HDAC6 Inhibitor
HDAC6-IN-6 is a potent inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 0.025 μM. This compound is capable of crossing the blood-brain barrier and demonstrates strong inhibitory activity against amyloid-beta peptide (Aβ1-42) self-aggregation and acetylcholinesterase (AChE) with IC50 values of 3.0 μM and 0.72 μM, respectively. Additionally, HDAC6-IN-6 enhances neurite outgrowth while maintaining a favorable safety profile, making it a valuable tool for research in neurodegenerative diseases and related fields. -
AChE/SERT Inhibitor
BGC-201259 is a potent and orally active inhibitor of acetylcholinesterase (AChE) and serotonin transporter (SERT), with IC50 values of 101 nM and 42 nM, respectively. Additionally, it inhibits the 5-HT receptor with an IC50 of 90 nM. BGC-201259 exhibits varying activity against several targets, including the norepinephrine transporter (IC50 = 7.7 μM), L-type calcium channel (IC50 = 3.6 μM), σ receptor (IC50 = 2 μM), and sodium channel (IC50 = 5.1 μM). This compound shows promise in research related to Alzheimer's disease by potentially enhancing cognitive and emotional functions through its dual-targeting mechanism. -
AChE Inhibitor
Flucopride is an AChE inhibitor with an IC50 of 24 nM, demonstrating significant potency in acetylcholinesterase modulation. Additionally, it acts as a partial agonist at the 5-HT4 receptor with a binding affinity (Ki) of 9.6 nM. Flucopride facilitates non-amyloidogenic processing of amyloid precursor protein (APP) in COS-7 cells expressing the human 5-HT4 receptor, with an EC50 of 23.0 nM. Its properties suggest effective gastrointestinal tract penetration and the capability to cross the blood-brain barrier, as indicated by PAMPA assay results, making it relevant for neuropharmacology research. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-1 is a selective dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), with IC50 values of 4 nM and 8.9 nM, respectively. This compound demonstrates significant potential in ameliorating cognitive impairment in an Aβ1–42-induced mouse model, making it a valuable tool in Alzheimer's disease research. Its ability to modulate both cholinergic and epigenetic pathways positions BChE/HDAC6-IN-1 as a promising candidate for studies focused on neurodegenerative disorders. -
Anti-inflammatory agent, AChE Inhibitor, P450 Inhibitor, Neuroprotective agents
Acetylshikonin is a potent anti-inflammatory agent that also functions as an inhibitor of acetylcholinesterase (AChE) and non-selective cytochrome P450 enzymes. With an IC50 of 34.6 μM for AChE, Acetylshikonin exhibits neuroprotective properties and can induce apoptosis and autophagy in cancer cells. Its ability to regulate blood glucose and liver fat metabolism makes it valuable in research related to diabetes, diabetic nephropathy, obesity, and nonalcoholic fatty liver disease. -
Cholinesterase (ChE) Inhibitor
Scopoletin is a cholinesterase inhibitor that primarily targets acetylcholinesterase (AChE). It possesses notable biological activity in preventing the breakdown of acetylcholine, thereby enhancing cholinergic transmission. Scopoletin is commonly used in research focused on neurodegenerative diseases, cognitive disorders, and potential therapeutic interventions involving cholinergic systems. -
Cholinesterase (ChE) Inhibitor
(-)-Corynoxidine is an acetylcholinesterase (ChE) inhibitor with an IC50 of 89.0 μM, derived from the aerial parts of Corydalis speciosa. This compound demonstrates antibacterial activity against Staphylococcus aureus, including methicillin-resistant strains, making it a valuable tool for research in neurology and antimicrobial studies. -
Bacterial Inhibitor
Medicagenic acid, a potent bacterial inhibitor derived from the roots of Herniaria glabra, demonstrates significant fungistatic activity against various plant pathogens and human dermatophytes. This compound exhibits low enzyme inhibitory activity, specifically targeting xanthine oxidase, collagenase, elastase, tyrosinase, and cholinesterase. Medicagenic acid is valuable for research applications in studying antifungal resistance mechanisms and exploring potential therapeutic avenues for dermatological conditions. -
Antioxidant/Antimicrobial Agent/Cholinesterase Inhibitor
2-Hydroxydocosanoic acid is a versatile compound known for its antioxidant properties, inhibition of cholinesterase, and antimicrobial activity. It has shown potential in mitigating oxidative stress, making it relevant for studies focused on neuroprotection and aging. Additionally, its antimicrobial effects support research applications in combating microbial resistance. This compound serves as a valuable tool for exploring mechanisms related to oxidative damage and microbial inhibition. -
AChE/BChE Inhibitor
Coumarin 106 is a dipolar laser dye that serves as an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). It exhibits mixed-type inhibition of AChE with a pIC50 of 4.97 and a Ki value of 2.36 μM, while also inhibiting BChE with a slightly lower potency (pIC50 of 4.56). This compound is valuable in studying cholinergic signaling pathways and may aid in the exploration of therapeutic strategies for disorders linked to cholinergic dysfunction. -
AChE/BChE Inhibitor
PE154 is a highly potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 280 pM and 16 nM, respectively. This compound is effective for visualizing β-amyloid plaques in histochemical analyses, making it a valuable tool in research focused on neurodegenerative diseases and cholinergic system studies. Its high specificity and sensitivity enhance its utility in biochemical assays and pathological examinations. -
AChE/hCA Inhibitor
AChE/hCA I-IN-1 is a selective inhibitor of acetylcholinesterase (AChE) and human carbonic anhydrases (hCA I and hCA II). It demonstrates potent inhibition with IC50 values of 302 nM for AChE, 265 nM for hCA I, and 283 nM for hCA II. This compound is valuable for research applications exploring neurodegenerative disorders and the regulation of physiological pH balance. -
AChE/hCA Inhibitor
AChE/hCA I/II-IN-1 is a potent inhibitor of acetylcholinesterase (AChE) and human carbonic anhydrases I and II (hCA I/II), demonstrating IC50 values of 22.21 nM for AChE, and 60.79 nM and 66.64 nM for hCA I and II, respectively. This compound is valuable for research applications related to glaucoma, Alzheimer’s disease, and diabetes, providing insights into the modulation of these critical enzymatic targets. -
hCA I/II Inhibitor
hCAI/II-IN-5 is a potent inhibitor of human carbonic anhydrase isoenzymes I and II, exhibiting IC50 values of 37.88 nM and 45.23 nM, respectively. Additionally, it demonstrates inhibitory activity against α-Glycosidase and acetylcholinesterase (AChE) with IC50 values of 48.98 nM and 420.14 nM. This compound is valuable for research applications in various diseases, including diabetes, Alzheimer's disease, heart failure, ulcers, and epilepsy. -
CA/ChE Inhibitor
hCA I-IN-4 is an inhibitor of carbonic anhydrase (CA) and cholinesterase (ChE), demonstrating potent inhibitory activity against hCA I, hCA II, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) with Ki values of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nM, respectively. This compound also exhibits cytotoxic effects in BT-549 cancer cells, with an IC50 value of 16.59 μM. hCA I-IN-4 is valuable for research involving enzyme regulation and cancer therapeutics. -
α-GLY Inhibitor
α-Glycosidase-IN-1 is a selective inhibitor of α-glycosidase (α-GLY), exhibiting a potent IC50 of 44.72 nM and a KI of 41.74 nM. Additionally, it demonstrates inhibitory activity against human carbonic anhydrase isoenzymes I and II, as well as acetylcholinesterase, with IC50 values of 104.87 nM, 100.04 nM, and 654.87 nM, respectively. This compound is valuable for research into various conditions, including diabetes, Alzheimer’s disease, heart failure, ulcers, and epilepsy. -
hCAI/II Inhibitor
hCAI/II-IN-8 is a hydrazide derivative that serves as a selective inhibitor of human carbonic anhydrase isomerases I and II, with IC50 values of 21.35 ± 0.39 nM and 7.12 ± 0.12 nM, respectively. In addition to its primary target, hCAI/II-IN-8 also demonstrates inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 46.27 ± 0.75 nM and 43.38 ± 0.83 nM, respectively. This compound is relevant for studies involving enzyme inhibition and has potential applications in understanding neurodegenerative diseases and carbonic anhydrase-related pathologies. -
AChE Inhibitor
hAChE-IN-6 is a selective acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 of 0.16 μM. It also inhibits human butyrylcholinesterase (hBuChE) and glycogen synthase kinase 3 beta (GSK3β) with IC50 values of 0.69 μM and 0.26 μM, respectively. Notably, hAChE-IN-6 inhibits the self-aggregation of tau protein and amyloid beta 1-42, making it a valuable reagent for research into Alzheimer's disease pathogenesis and therapeutic strategies. -
AChE/BACE1/GSK3β Inhibitor
AChE/BACE1/GSK3β-IN-1 is a potent triple inhibitor targeting acetylcholinesterase (AChE), beta-secretase 1 (BACE1), and glycogen synthase kinase 3 beta (GSK3β). It demonstrates effective inhibitory activity with IC50 values of 1.0 μM for AChE, 20 μM for BACE1, and 15 μM for GSK3β. With favorable blood-brain barrier penetrability and bioavailability, AChE/BACE1/GSK3β-IN-1 is a valuable tool for research into Alzheimer's disease mechanisms and therapeutics. -
AChE/GSK-3β Inhibitor
ZLWH-23 is a selective inhibitor of acetylcholinesterase (AChE) with an IC50 of 0.27 μM and also inhibits glycogen synthase kinase-3 beta (GSK-3β) with an IC50 of 6.78 μM. It exhibits greater selectivity for AChE compared to butyrylcholinesterase (BChE) and shows preferential inhibition of GSK-3β over a range of multi-kinases. This compound is relevant for research focused on Alzheimer's disease pathophysiology. -
AChE/GSK-3β Inhibitor
PJ17 is a potent dual inhibitor of acetylcholinesterase (AChE) and glycogen synthase kinase 3 beta (GSK-3β), exhibiting IC50 values of 8.84 μM and 4.19 μM, respectively. This compound demonstrates a lack of significant neurotoxicity in primary cerebellar granule neuron cultures, making it a promising candidate for neuropharmacological studies. PJ17 serves as a valuable template for the development of multitarget therapeutics and is relevant in research focused on Alzheimer's disease. -
hAChE/hBuChE Inhibitor
hAChE-IN-5 is a potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting IC50 values of 0.17 μM for both enzymes. In addition, hAChE-IN-5 demonstrates significant GSK3β inhibition with an IC50 of 0.21 μM. This compound is utilized in research focused on tau protein aggregation and Aβ1-42 self-aggregation, effectively preventing Aβ-dependent neurotoxicity. Furthermore, hAChE-IN-5 can cross the blood-brain barrier, showcasing its potential as a multi-targeted agent in the study of Alzheimer's disease. -
ACE Inhibitor
Ovotransferrin (328-332) is an Angiotensin-Converting Enzyme (ACE) inhibitor that demonstrates protective effects on blood pressure, with an IC50 of 20 μM. Additionally, this fragment exhibits activity against Cholinesterase (ChE), highlighting its potential relevance in Alzheimer's disease research. Its dual inhibitory mechanisms make it a valuable tool for studying cardiovascular health and neurodegenerative disorders. -
AChE Inhibitor
Coumaran, also known as 2,3-Dihydrobenzofuran, is an inhibitor of acetylcholinesterase (AChE) and exhibits notable antileishmanial activity. Its mechanisms include the activation of macrophages, contributing to its antiparasitic effects and immunomodulatory properties. Coumaran is also applicable in the field of biopesticides, providing a potential tool for agricultural and biological research. -
ChE Inhibitor
N-p-trans-Coumaroyltyramine is a natural phenolic amide compound that acts as an inhibitor of acetylcholinesterase (AChE) with an IC50 of 122 μM and α-glucosidase with an IC50 of 2.7 μM. It demonstrates significant anti-trypanosomal activity, exhibiting an IC50 of 13.3 µM against Trypanosoma brucei rhodesiense. This compound is valuable for research into neurodegenerative diseases such as Alzheimer's disease, as well as for studies focusing on trypanosomiasis. -
Parasite Inhibitor
Diazinon is an irreversible acetylcholinesterase (AChE) inhibitor with primary applications in pest control as an insecticide. By inhibiting AChE, Diazinon leads to the accumulation of acetylcholine, resulting in overstimulation of acetylcholine receptors and disruption of nervous system function. Additionally, Diazinon generates reactive oxygen species (ROS), contributing to oxidative stress across various biological tissues. This compound is predominantly utilized in agricultural settings but may also hold implications for human and animal health research. -
AChE Inhibitor
Carbosulfan is an orally active acetylcholinesterase (AChE) inhibitor that hydrolyzes to carbofuran, leading to significant insecticidal properties. This compound demonstrates broad-spectrum insecticidal activity while inducing oxidative stress through increases in lipid peroxidation and impairment of antioxidant defenses. Carbosulfan is associated with reproductive toxicity in male rats and developmental disorders in offspring, making it a relevant subject in studies focused on reproductive toxicity and environmental risk assessment. Its persistence in aquatic environments raises concerns regarding potential hazards to non-target organisms. -
Parasite Inhibitor
8-Deoxygartanin, a prenylated xanthone derived from Garcinia mangostana, serves as a selective inhibitor of butyrylcholinesterase (BChE). This compound demonstrates significant antiplasmodial activity, with an IC50 value of 11.8 μM against the W2 strain of Plasmodium falciparum. Additionally, 8-Deoxygartanin inhibits NF-κB (p65) activation, displaying an IC50 of 11.3 μM, making it a valuable reagent for research in parasitic infections and inflammation pathways. -
Cholinesterase (ChE) Inhibitor
Fenchlorphos is an organophosphate compound that acts as a potent inhibitor of acetylcholinesterase (AChE), an important enzyme in cholinergic signaling. By disrupting AChE activity, Fenchlorphos leads to the accumulation of acetylcholine, resulting in increased cholinergic neurotransmission. Additionally, this compound has been shown to induce mitochondrial dysfunction, making it a valuable tool for research on neurobiology and toxicology. Its applications include studies on the mechanisms of insecticide action and investigations into the impacts of cholinergic inhibition on cellular metabolism. -
Parasite Inhibitor
Phosalone is an organophosphate insecticide that primarily targets acetylcholinesterase, leading to the inhibition of neurotransmission in parasites. Its potent biological activity makes it effective in controlling a wide range of insect pests. Phosalone is utilized in entomological research and in studies focusing on pest management strategies and the biochemical pathways of insecticide resistance. -
ChE Inhibitor
Isogarcinol is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 1.13 μM and 8.30 μM, respectively. This compound also demonstrates significant leishmanicidal activity, with an IC50 of 0.33 μM against Leishmania donovani. Isogarcinol's dual action makes it a valuable tool for research in neurodegenerative disorders and parasitic diseases. -
BChE Inhibitor/CB2R Agonist
hBChE-IN-2 is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 of 0.62 μM and functions as an agonist for cannabinoid receptor 2 (CB2R). This compound exhibits significant neuroprotective activities, making it a valuable tool in the study of neurodegenerative diseases and cannabinoid signaling pathways. Its dual action positions hBChE-IN-2 as an important reagent for research applications targeting cholinergic regulation and endocannabinoid modulation. -
Topoisomerase I Inhibitor
RPR121056 is a topoisomerase I inhibitor that functions as a metabolite of the chemotherapy agent Irinotecan (CPT-11), produced by the enzyme CYP3A4. This compound induces cell death by disrupting DNA replication, making it relevant for cancer research, particularly in the context of colorectal cancer treatment. Additionally, RPR121056 demonstrates direct inhibition of acetylcholinesterase (AChE), further expanding its potential applications in pharmacological studies. -
AChE/Dopamine 2 Inhibitor
Itopride is a potent dopamine D2 receptor antagonist and an acetylcholinesterase (AChE) inhibitor. Itopride enhances gastric motility through its dual mechanisms of action, promoting both antidopaminergic and anti-acetylcholinesterase effects. This compound is primarily utilized in research related to gastrointestinal disorders, particularly gastroesophageal reflux disease (GERD), offering insights into prokinetic therapies. -
AChE Inhibitor
Temephos is an organophosphate insecticide that functions as an irreversible inhibitor of acetylcholinesterase (AChE). This inhibition leads to cholinergic overactivation, effectively disrupting the larval development of Aedes aegypti and Aedes albopictus, making it a valuable tool in research concerning Dengue Virus, Zika Virus, and other mosquito-borne pathogens. While exhibiting important biological activity, Temephos has been shown to cause genotoxicity, neurodevelopmental toxicity, and potential liver and reproductive system effects in mammals. Additionally, it can accumulate in adipose tissues and aquatic organisms, with its metabolism primarily occurring through oxidation and hydrolysis. Temephos serves as a critical reagent in studies of vector control and viral transmission dynamics. -
SMase Inhibitor
SMase-IN-1 is a specific inhibitor of bacterial sphingomyelinase (SMase), exhibiting an IC50 value of 6.43 µM against B. cereus SMase. In addition to its primary activity, SMase-IN-1 also demonstrates a significant inhibition rate of 59.50% for equine butyrylcholinesterase (eqBuChE) at a concentration of 50 µM. This compound forms a complex with Cu2+ in biometal interactions and effectively reduces hemolysis induced by B. cereus in sheep erythrocytes. SMase-IN-1 is valuable for research in microbial pathogenesis and enzyme inhibition studies. -
Cholinesterase (ChE) Inhibitor
N-Desmethyl Galanthamine is a potent cholinesterase inhibitor, specifically targeting acetylcholinesterase (AChE) with an IC50 value of 2.76 μM. As a metabolite of Galanthamine, it holds significant relevance in neuropharmacological research. This compound is utilized in studies related to Alzheimer's disease, providing insights into therapeutic strategies aimed at enhancing cholinergic transmission. -
AChE Inhibitor
3-Hydroxycarbofuran is a reversible inhibitor of acetylcholinesterase (AChE), acting primarily by competing with acetylcholine at the enzyme's active site. This compound serves as a significant metabolite of Carbofuran and exhibits notable biological activity in the modulation of cholinergic signaling. It is utilized in research related to neurobiology, toxicology, and pesticide biochemistry, providing insights into the effects of AChE inhibition on synaptic transmission and potential neurotoxic mechanisms.
